Rotigotine transdermal patch in the treatment of Parkinson’s disease and restless legs syndrome
Authors:
- Christopher KenneyCKChristopher Kenney
- Joseph JankovicJJJoseph Jankovic
- 11 June 2007
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 8 (9) , 1329-1335
Abstract
Dopamine agonists are effective in delaying levodopa-induced dyskinesia in early Parkinson's disease (PD) and reducing motor fluctuations in advanced PD. Rotigotine, a novel dopamine receptor agonist, improves motor function in both early and advanced PD using a transdermal route of administration. A smaller, but convincing body of data, supports its ability to ameliorate the symptoms of restless legs syndrome as well. The side-effect profile mimics other dopamine agonists, with the addition of application-site reactions, most of which are mild-to-moderate. Advantages over existing dopamine agonists include once-daily administration, absence of food interactions, maintenance of stable plasma levels and utility in patients with swallowing difficulties.Keywords
This publication has 31 references indexed in Scilit:
- Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson’s diseaseExpert Opinion on Drug Delivery, 2007
- Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's diseaseExperimental Neurology, 2007
- Rotigotine transdermal system for perioperative administrationJournal of Neural Transmission, 2006
- Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson DiseaseArchives of Neurology, 2006
- Rotigotine Transdermal Patch Enables Rapid Titration to Effective Doses in Advanced-Stage Idiopathic Parkinson DiseaseClinical Neuropharmacology, 2006
- Safety, Tolerability, and Efficacy of Continuous Transdermal Dopaminergic Stimulation with Rotigotine Patch in Early-Stage Idiopathic Parkinson DiseaseClinical Neuropharmacology, 2005
- Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: A double‐blind, placebo‐controlled pilot studyMovement Disorders, 2004
- Dopamine agonists in Parkinson’s diseaseExpert Opinion on Investigational Drugs, 2003
- N‐0923, A novel soluble dopamine D2 agonist in the treatment of parkinsonismMovement Disorders, 1998
- N‐0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's diseaseMovement Disorders, 1994